Goldman SachsGSBUYSep 11, 2024Stock price when the opinion was issued
As of Jul 20, 2026. Market Open.
Different businesses. LLY is a big play in GLP-1 drugs. How will pills effect the injections business? LLY has done a good job of navigating these new pills. GS enjoys increased stock market and IPO businesses. He prefers LLY, which is tied to a secular growth trend, but GS' good times in capturing revenue in this cycle will end.
Mergers are increasing, and banks like GS makes advisory fees from them. Also, the banks have been rallying since oil slumped, and will benefit further from rising interest rates, which appears will happen later this year. Plus, hyperscalers may need to keep borrowing money to keep competing with each other.
He bought more GS this week. Their credit cards have been their major overhang; they announced they will get out of the consumer business and are close to a deal with Barclays. The charge-offs could be 10%, twice the industry norm. And who will take the Apple credit cards off their hands? These won't impact GS long term. They did give a target of raising $225 billion in third-party assets to support their wealth management business, which they've already surpassed. Their pipeline has increased a lot, too. Trading revenues are -10%, but last year's comps were so great. Is trading a little over 11x PE 2025.